Valley Diagnostics
Urine-based lateral flow test for early, accessible prostate cancer detection
| Deal Type | Equity |
|---|---|
| Sector | HealthTech & Digital Health |
| Geography | United Kingdom |
| Stage / Vintage | Seed / translational development |
| Total Fundraise | GBP 0.7M seed in progress; GBP 1.7M planned |
| Minimum Ticket | N/D |
Opportunity Overview
Valley Diagnostics is developing a lateral flow test to diagnose prostate cancer from urine samples. The company is building on seven years of small-molecule metabolite biomarker discovery at Aberystwyth University, led by Prof Luis Mur, with a five-biomarker fingerprint intended to detect prostate cancer earlier, faster and at lower cost than existing early screening routes. The test is designed for 10 to 15 minute use in home, primary care or local settings, with cloud-based AI quantification. Valley Diagnostics states that the approach can detect prostate cancer biomarkers in urine with up to 94% accuracy, an NPV of 99.5%, and the potential to distinguish prostate cancer from benign prostatic hyperplasia.
Key Highlights
- Simple urine-sample lateral flow format designed for low-cost, decentralised prostate cancer screening.
- Up to 94% accuracy and 99.5% negative predictive value cited in the executive summary.
- Global licence rights to IP arising from Aberystwyth University metabolomics research.
- Patents granted or pending across biomarker fingerprints and supporting biomarker technology.
- Funding plan includes a GBP 0.7M seed round in progress and a further GBP 1.7M seed round planned for Q4 2026.
GCC Relevance
Prostate cancer screening, early diagnostics and decentralised testing are relevant to GCC health-system prevention and primary-care strategies. Valley could be positioned with regional medtech distributors, diagnostics groups and hospital networks, though the supplied summary does not identify existing GCC traction.